The Safety and Effectiveness of Hyperimmune Anti-HIV Intravenous Immunoglobulin (HVIG) Plus Zidovudine in HIV-Infected Infants

Inclusion Criteria Concurrent Medication: Allowed: Recommended: Standard immunizations. Should repeat MMR 3 months after discontinuing study. Benadryl and/or aspirin. Pneumocystis carinii pneumonia prophylaxis. Systemic ketoconazole and acyclovir, or oral nystatin for acute therapy. Aerosol ribavirin for short-term treatment of RSV. Concurrent Treatment: Allowed: Blood transfusion. Patients must have the following: Parent or guardian available to give written informed consent. Protocol requires prior Institutional Review Board (IRB) approval before any subject is entered into study. Prior Medication: Allowed: Gammaglobulin, intravenous (IV) or intramuscular (IM). Immunoglobulin, IV (IVIG). Maternal antiretroviral treatment during pregnancy. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: Symptomatic of any class P-2 symptoms (except lymphadenopathy at time of study entry. Presence of serious acute infection requiring parenteral treatment at time of study entry. Concurrent Medication: Excluded: Prophylaxis for oral candidiasis or otitis media or other infections. Immunoglobulin therapy (except single dose or for hypogammaglobulinemia). Ketoconazole, acyclovir, or nystatin for prophylaxis. Patients with the following are excluded: Symptomatic of any class P-2 symptoms (except lymphadenopathy at time of study entry. Presence of serious acute infection requiring parenteral treatment at time of study entry. Prior Medication: Excluded: Antiretroviral treatment or experimental treatment within 2 weeks of entry.